Login

Siyuan Yan

ORCID: 0000-0001-8971-0508
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5052160010
Research Areas
  • Hedgehog Signaling Pathway Studies
  • Chromatin Remodeling and Cancer
  • Genomic variations and chromosomal abnormalities
  • Cancer-related Molecular Pathways
  • Genetics and Neurodevelopmental Disorders
  • Epigenetics and DNA Methylation

Shanghai Jiao Tong University
 2024

Renji Hospital
 2024

 Targeting Super-Enhancer-Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance
OPENALEX - Publications 
Yi Sui Teng Wang Yanqing Mei Ying Zhu Wenyan Jiang and 7 more Jiayi Shen Siyuan Yan Wenjie Lu Kewen Zhao Jialin Mo Chaochen Wang Yujie Tang

Aberrant activation of the Hedgehog (Hh) signaling pathway plays important roles in oncogenesis and therapeutic resistance several types cancer. The clinical application FDA-approved Hh-targeted smoothened inhibitors (SMOi) is hindered by emergence primary or acquired drug resistance. Epigenetic transcriptional-targeted therapies represent a promising direction for developing improved anti-Hh therapies. In this study, we integrated epigenetic/transcriptional-targeted small-molecule library...

10.1158/0008-5472.can-23-3306 article EN Cancer Research 2024-05-22
 Data from Targeting Super-Enhancer–Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance
OPENALEX - Publications 
Yi Sui Teng Wang Yanqing Mei Ying Zhu Wenyan Jiang and 7 more Jiayi Shen Siyuan Yan Wenjie Lu Kewen Zhao Jialin Mo Chaochen Wang Yujie Tang

<div>Abstract<p>Aberrant activation of the Hedgehog (Hh) signaling pathway plays important roles in oncogenesis and therapeutic resistance several types cancer. The clinical application FDA-approved Hh-targeted smoothened inhibitors (SMOi) is hindered by emergence primary or acquired drug resistance. Epigenetic transcriptional-targeted therapies represent a promising direction for developing improved anti-Hh therapies. In this study, we integrated...

10.1158/0008-5472.c.7403464 preprint EN 2024-08-15
 Supplementary Figures S1-S15 and Figure Legends and Table Legends from Targeting Super-Enhancer–Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance
OPENALEX - Publications 
Yi Sui Teng Wang Yanqing Mei Ying Zhu Wenyan Jiang and 7 more Jiayi Shen Siyuan Yan Wenjie Lu Kewen Zhao Jialin Mo Chaochen Wang Yujie Tang

<p>The PDF file includes Supplementary Figures S1-S15, Figure Legends, and Table Legends</p>

10.1158/0008-5472.26710849.v1 preprint EN cc-by 2024-08-15
 Data from Targeting Super-Enhancer–Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance
OPENALEX - Publications 
Yi Sui Teng Wang Yanqing Mei Ying Zhu Wenyan Jiang and 7 more Jiayi Shen Siyuan Yan Wenjie Lu Kewen Zhao Jialin Mo Chaochen Wang Yujie Tang

<div>Abstract<p>Aberrant activation of the Hedgehog (Hh) signaling pathway plays important roles in oncogenesis and therapeutic resistance several types cancer. The clinical application FDA-approved Hh-targeted smoothened inhibitors (SMOi) is hindered by emergence primary or acquired drug resistance. Epigenetic transcriptional-targeted therapies represent a promising direction for developing improved anti-Hh therapies. In this study, we integrated...

10.1158/0008-5472.c.7403464.v1 preprint EN 2024-08-15
 Supplementary Figures S1-S15 and Figure Legends and Table Legends from Targeting Super-Enhancer–Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance
OPENALEX - Publications 
Yi Sui Teng Wang Yanqing Mei Ying Zhu Wenyan Jiang and 7 more Jiayi Shen Siyuan Yan Wenjie Lu Kewen Zhao Jialin Mo Chaochen Wang Yujie Tang

<p>The PDF file includes Supplementary Figures S1-S15, Figure Legends, and Table Legends</p>

10.1158/0008-5472.26710849 preprint EN cc-by 2024-08-15
Coming Soon ...